Literature DB >> 19478257

Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study.

Ener C Dinleyici1, Makbule Eren, Zeynel A Yargic, Nihal Dogan, Yvan Vandenplas.   

Abstract

The aim was to evaluate the efficacy of Saccharomyces boulardii (Sb) in addition to metronidazole in amebiasis. A prospective, randomized, open clinical trial was performed in 50 children presenting with acute bloody diarrhea caused by Entameba histolytica. Group A and B (each N = 25) was treated with metronidazole, but Sb (250 mg, twice daily) during the 7 days was added to Group B patients who were re-evaluated 2, 3, 5, 10, and 30 days after diagnosis. Duration of bloody diarrhea was significantly longer in Group A (72.0 +/- 28.5 versus 42.2 +/- 17.4 hours, P < 0.001). On day 5, amebic cysts had disappeared in all children in Group B, whereas in Group A, amebic cysts were still present in 6 children (P < 0.05). On day 10, all children were cured and cysts had disappeared in all. The addition of Sb to metronidazole in amebiasis significantly decreases duration of (bloody) diarrhea and enhances clearance of cysts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478257

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection.

Authors:  Ener Cagri Dinleyici; Makbule Eren; Nihal Dogan; Serap Reyhanioglu; Zeynel Abidin Yargic; Yvan Vandenplas
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  The Potential of Lactobacillus casei and Entercoccus faecium Combination as a Preventive Probiotic Against Entamoeba.

Authors:  Nitya Sarjapuram; Niharika Mekala; Meetali Singh; Utpal Tatu
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

3.  Clinical efficacy comparison of Saccharomyces boulardii and yogurt fluid in acute non-bloody diarrhea in children: a randomized, controlled, open label study.

Authors:  Makbule Eren; Ener C Dinleyici; Yvan Vandenplas
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

4.  Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

Authors:  Gamze Demirel; Istemi Han Celik; Omer Erdeve; Sibel Saygan; Ugur Dilmen; Fuat Emre Canpolat
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

5.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

6.  Antiamoebic drugs for treating amoebic colitis.

Authors:  Maria Liza M Gonzales; Leonila F Dans; Juliet Sio-Aguilar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-09

Review 7.  Intestinal microbiota and health in childhood.

Authors:  Yvan Vandenplas; Genevieve Veereman-Wauters; Elisabeth DE Greef; Tania Mahler; Thierry Devreker; Bruno Hauser
Journal:  Biosci Microflora       Date:  2011-11-17

Review 8.  Modulating the Gut Micro-Environment in the Treatment of Intestinal Parasites.

Authors:  Luis Vitetta; Emma Tali Saltzman; Tessa Nikov; Isabelle Ibrahim; Sean Hall
Journal:  J Clin Med       Date:  2016-11-16       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.